Advisory Assistance

In Canada, at the market introduction stage of a new patented drug (earlier of NOC and first sale), manufacturers are required to provide therapeutic product information, as well as the pricing position for their new drug, to the Patented Medicine Prices Review Board (PMPRB).

This information is needed before the PMPRB can assign a category for your drug and set a maximum allowed price.

At Brogan, our team of professionals will prepare or review these submissions for you and provide reliable feedback and strategic options. Our years of experience with the PMPRB puts us in a great position to help you achieve your pricing objectives.

For more information, please contact Brogan Inc. Price Regulation Consulting team at 613.599.0711 ext 255.